Becton Dickinson at a Crossroads: Diagnostics on the Fence
Executive SummaryBD has been doing well recently, but CEO Clateo Castellini wants to do even better--doubling revenues and profits in the next five years. That puts pressure on a company known for exploiting mature product lines. BD's diagnostics business, in particular, faces the challenge of keeping up in a rapidly consolidating segment as it goes head-to-head for the first time with the industry's heavy hitters.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.